OptiNose’s (NASDAQ:OPTN) quiet period will expire on Wednesday, November 22nd. OptiNose had issued 7,500,000 shares in its initial public offering on October 13th. The total size of the offering was $120,000,000 based on an initial share price of $16.00. During the company’s quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Several brokerages have recently issued reports on OPTN. Royal Bank Of Canada began coverage on OptiNose in a report on Tuesday, November 7th. They set an “outperform” rating and a $33.00 price objective on the stock. Jefferies Group LLC assumed coverage on OptiNose in a report on Tuesday, November 7th. They set a “buy” rating and a $27.00 price objective on the stock. BMO Capital Markets assumed coverage on OptiNose in a report on Tuesday, November 7th. They set an “outperform” rating and a $29.00 price target on the stock. Finally, Piper Jaffray Companies assumed coverage on OptiNose in a report on Tuesday, November 7th. They set an “overweight” rating and a $27.00 price target on the stock.

COPYRIGHT VIOLATION WARNING: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.dailypolitical.com/2017/11/18/optinose-inc-s-quiet-period-to-expire-on-november-22nd-nasdaqoptn.html.

Shares of OptiNose (NASDAQ:OPTN) opened at $15.75 on Friday. OptiNose has a twelve month low of $15.01 and a twelve month high of $21.46.

OptiNose Company Profile

OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.

Receive News & Ratings for OptiNose Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose Inc. and related companies with MarketBeat.com's FREE daily email newsletter.